Neon Therapeutics has entered into a collaborative research agreement with the Netherlands Cancer Institute’s (NKI) Antoni van Leeuwenhoek Hospital and the Amsterdam Biotherapeutics Unit.
Under the terms of the agreement, Neon Therapeutics and NKI will combine complementary capabilities to develop personalized T cell therapeutics.
The work will leverage the research by John Haanen, M.D., Ph.D., professor and head of the Medical Oncology Division at NKI, and Neon co-founder Ton Schumacher, Ph.D., professor and senior member of the Department of Immunology and deputy director of NKI.
Drs. Haanen and Schumacher have focused their research interests on the development and evaluation of adoptive T cell cancer therapies, and the role of neoantigens in the anti-tumor immune response. Building on this expertise, the project aims to generate neoantigen-specific T cells for the personalized treatment of cancer.
“We are excited to collaborate with Neon Therapeutics to develop personalized cell therapies for cancer patients,” said Dr. Haanen.
“Together we look forward to developing a process that could potentially lead to manufacturing of these neoantigen T cell products in our GMP facilities, and leveraging our world-leading clinical resources for clinical development.”
Neon Therapeutics interim CEO Cary Pfeffer said: “Neon Therapeutics is proud to join forces with the Netherlands Cancer Institute, an internationally renowned research and clinical institution.
“Collaborative research with this esteemed institute will enable accelerated development of our personalized T cell program, which we believe may become an important new class of cancer immunotherapies by leveraging neoantigens as optimal immune targets.”